培美曲塞联合铂类治疗难治性晚期乳腺癌疗效与安全性分析  

Clinical effect and safety of Pemetrexed combined with Platinum in advanced metastatic breast cancer

作　　者：李丹[1] 朱悦茗[1] 谢芳[1] 吴学勇[1] 

机构地区：[1]上海市静安区中心医院(复旦大学附属华山医院静安分院)肿瘤内科,上海200040

出　　处：《现代肿瘤医学》2015年第2期200-202,共3页Journal of Modern Oncology

摘　　要：目的:通过观察分析培美曲塞联合铂类药物治疗晚期乳腺癌的疗效及毒副反应,探寻难治性复发转移性乳腺癌的有效治疗方法。方法:选择60例晚期乳腺癌患者,根据体质不同予以培美曲塞联合顺铂或奥沙利铂方案化疗:培美曲塞500mg/m2,第1天;顺铂75mg/m2或奥沙利铂85mg/m2,第1天;每3周一疗程,每2个疗程进行1次疗效和安全性评价。结果:60例患者均可评价疗效,中位随访14个月,PR 22例,SD 20例,RR 36.7%,中位PFS 4.5个月(95%CI:3-11个月),中位OS 8.2个月(95%CI:7.5-12个月)。主要毒副反应为疲乏,其次为白细胞减少、胃肠道反应、末梢神经炎,但均较轻微。结论:培美曲塞联合铂类方案治疗复发转移性乳腺癌疗效值得肯定,毒副反应轻微,且无论联合顺铂或奥沙利铂生存率无明显差别,患者能够耐受。Objective：To observe the efficacy and toxicity of Pemetrexed combined with Platinum in the treatment of advanced metastatic breast cancer（MBC） patients.Methods：According to the different physique,60 MBC patients received Pemetrexed combined with Cisplatin/Oxaliplatin chemotherapy.The patients received Pemetrexed 500mg/m2 on day 1,and Cisplatin 75mg/m2 or Oxaliplatin 85mg/m2 on day 1,intravenous infusion,with 3 weeks as a cycle.Evaluation of response and adverse reactions were practiced every 2 cycles.Results：With a median follow-up of 14 months,60 patients were evaluable,with RR 36.7％,PFS 4.5 months（95％ CI：3-11 months）,OS 8.2 months （95％ CI：7.5-12 months）.The most common adverse reaction were fatigue,white blood cells decrease and the digestive tract reactions,followed by peripheral neuritis.Conclusion：Pemetrexed combined with Platinum in the treatment of patients with advanced metastatic breast cancer could effectively improve quality of life,and also with low rate of adverse reactions.There is no remarkable difference between the Cisplatin and the Oxaliplatin group on the survival rate.

关 键 词：培美曲塞 转移性乳腺癌 顺铂/奥沙利铂 

分 类 号：R737.9[医药卫生—肿瘤]